Stock Price & Analysis

The S1 support level for CGON Stock is $27.06 ,The R1 resistant level for CGON Stock is $30.01.

As of the end of day on 2025-02-21, the price of CGON Stock was $28.43.

The target price for CGON Stock according to analyst rating is 68.80, with the highest price target at 83.00 and the lowest at 55.00. Analysts have a Strong Buy rating on CGON Stock overall.

The market cap of CGON is $2.1B.

CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene is initially in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its lead candidate, BOND-003 is a targeted oncolytic intravesically delivered immunotherapy agent that is in Phase II for the treatment of Bacillus Calmette Guerin (BCG) unresponsive and intermediate risk NMIBC disease. Its other product candidate CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).

CGON has a total of 61 employees.